Autoimmune diseases refer to a group of approximately 100 different diseases in which the body’s immune system, mistakenly attacks and destroys a patient’s own tissue and/or organ (self). There is currently no cure for autoimmune diseases, and current treatments rely on general, non-specific suppression of immune system function, frequently resulting in unacceptable side effects including infection and cancer.
There is a large unmet need for improved treatments that can suppress immune activity (restore immune tolerance) to a patients own tissue without causing generalized immune suppression.
Navacims create disease-specific immune suppression, while avoiding the general immune suppression associated with current therapies. Parvus’ innovative approach has the potential to benefit millions of patients suffering from different autoimmune diseases and chronic inflammatory conditions.
Navacims reprogram disease-associated, autoantigen-experienced T cells (effectors) to differentiate and expand into regulatory T (Treg) cells (suppressors) specific to the patient’s disease. These disease-specific Tregs selectively reverse autoimmune disease by suppressing autoimmune attacks on self without impairing normal immune function.
Parvus has retained unencumbered rights to all Navacims and all indications and is advancing our robust pipeline of proprietary Navacim drug candidates towards clinical testing. Parvus’ leadership team possesses deep experience in drug discovery, development, and commercialization in diverse disease areas, including immunology and autoimmune disease.
Industry leaders with proven track records in advancing innovative therapies through development to commercialization
If you are interested in discussing a collaboration or partnership opportunity, contact email@example.com.